ABROGATE - Novel diagnosis and treatment of food allergies

Food allergies are increasing and are not only associated with a major reduction in quality of life, but can also cause life-threatening anaphylactic reactions. The reliable diagnosis of allergic hypersensitivity to certain foods is currently only feasible with an elaborate food challenge test.

The aim of the ABROGATE association is to find novel solutions for diagnosis and treatment for people with allergic hypersensitivity to food. For this purpose, the interaction of various allergy-regulating factors, such as environmental exposure, barrier function of skin and mucous membrane surfaces, the composition of the microbiome as well as innate and adaptive immune responses will be analyzed in cohort studies in order to identify intolerance mechanisms and new diagnostic biomarkers.

In the long term, the results of the ABROGATE network could establish an endotype-specific diagnosis of food allergies, which could expand or even replace the existing diagnosis with a food challenge test. On the other hand, allergen-specific immunotherapy could be further developed through findings on the use of probiotics.

The ADAPT solution combines two innovations, a non-invasive nasal sampling device and a new set of biomarkers, to create a novel diagnostic kit that permits earlier, more precise assessment of inflammatory respiratory disease, thereby facilitating better intervention and personalised treatment. 
ADAPT is lead by TUM Klinikum rechts der Isar.TUM works with partners from Phadia AB (Thermo Fisher Scientific), Rheinisch-Westfaelische Technische Hochschule Aachen, Universitätsklinikum Aachen and Uniwersytet Medyczny w Łodzi to provide expertise in producing the panel of biomarkers.
Vienna Challenge Chamber are leading experts in pollen exposure studies. Hunt Developments (UK) limited and Imperial College London contribute their work on the diagnostic device.

 

 
  • Asthma research and epithelial biology.
  • The group is pursuing basic and applied research.
  • Aim is to explore epithelial biology
  • ...and B) identify biomarker and drug targets  
 
            

 

DFG funded graduate school RTG2668

Immune Master Switches in Allergies and Autoimmune Diseases IMS – A2D

There is a constant increase in the prevalence of both, allergies and autoimmune diseases in developed and developing countries. Although ongoing efforts in research have improved, our understanding of the immune mechanisms involved in these complex diseases, the exact cascades of events driving disease development are still unknown. Therefore, this RTG was set up to identify immune master switches (IMS) guiding directed disease development in allergies and autoimmune diseases for an in-depth understanding necessary for precise diagnostic measures and novel, mechanism-based treatment strategies. This RTG will combine unique expertise, methods, and models from the scientific TUM environment of translational research to raise our understanding of allergies and autoimmune diseases to a next level and provide unprecedented training, qualification, and career support to young researchers from life science and medicine.